{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T11:19:59Z","timestamp":1770290399385,"version":"3.49.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,11]],"date-time":"2022-03-11T00:00:00Z","timestamp":1646956800000},"content-version":"vor","delay-in-days":69,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100548","type":"journal-article","created":{"date-parts":[[2022,3,14]],"date-time":"2022-03-14T19:42:36Z","timestamp":1647286956000},"page":"100548","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-4714","authenticated-orcid":false,"given":"Peter F.G.","family":"Foulser","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishanthi","family":"Senthivel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Downey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul E.","family":"Hart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie E.","family":"McGrath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ctarc.2022.100548_bib0001","article-title":"Posterior reversible encephalopathy syndrome, part 1: fundamental imaging and clinical features","volume":"29","author":"Bartynski","year":"2008","journal-title":"Am. J. Neuroradiol."},{"key":"10.1016\/j.ctarc.2022.100548_bib0002","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1007\/s00415-016-8377-8","article-title":"Posterior reversible encephalopathy syndrome","volume":"264","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.ctarc.2022.100548_bib0003","first-page":"915","article-title":"Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions","volume":"14","author":"Fugate","year":"2015","journal-title":"L Neurol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100548_bib0004","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3174\/ajnr.A0960","article-title":"Posterior reversible encephalopathy syndrome after solid organ transplantation","author":"Bartynski","year":"2008","journal-title":"AM J. Neuroradiol."},{"issue":"5","key":"10.1016\/j.ctarc.2022.100548_bib0005","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1542\/peds.2014-2325","article-title":"PRES in children undergoing hematopoietic stem cell or solid organ transplantation","volume":"135","author":"Masetti","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ctarc.2022.100548_bib0006","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11912-014-0383-3","article-title":"Posterior reversible encephalopathy syndrome: a neurologic phenomenon in cancer patients","volume":"16","author":"Le","year":"2014","journal-title":"Curr. Oncol. Rep."},{"issue":"4","key":"10.1016\/j.ctarc.2022.100548_bib0007","doi-asserted-by":"crossref","DOI":"10.1111\/tbj.12776","article-title":"Reversible posterior leukoencephalopathy syndrome after eribulin mesylate chemotherapy for breast cancer","volume":"23","author":"Seol","year":"2017","journal-title":"Breast J."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100548_bib0008","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1200\/JOP.18.00643","article-title":"Palbociclib-induced posterior reversible encephalopathy syndrome: a previously unreported toxicity","volume":"15","author":"Harrold","year":"2019","journal-title":"J. Oncol. Practice"},{"issue":"3","key":"10.1016\/j.ctarc.2022.100548_bib0009","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.clbc.2012.01.006","article-title":"Reversible posterior leukoencephalopathy syndrome induced by vinorelbine","volume":"12","author":"Chen","year":"2012","journal-title":"Clin. Breast Cancer"},{"issue":"7","key":"10.1016\/j.ctarc.2022.100548_bib0010","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1634\/theoncologist.2014-0149","article-title":"Posterior reversible encephalopathy syndrome in patients with cancer","volume":"20","author":"Singer","year":"2015","journal-title":"Oncologist"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100548_bib0011","article-title":"Trastuzumab-associated posterior reversible encephalopathy syndrome","volume":"10","author":"Abughanimeh","year":"2018","journal-title":"Cureus"},{"issue":"5","key":"10.1016\/j.ctarc.2022.100548_bib0012","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/ccr3.2122","article-title":"Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non\u2013small-cell lung cancer","author":"Kim","year":"2019","journal-title":"Clin. Case Rep."},{"key":"10.1016\/j.ctarc.2022.100548_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/1078155215620922","article-title":"Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed hodgkin's lymphoma","volume":"23","author":"LaPorte","year":"2017","journal-title":"J. Oncol. Pharm. Pract."},{"key":"10.1016\/j.ctarc.2022.100548_bib0014","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1212\/CPJ.0000000000000362","article-title":"Nivolumab-induced posterior reversible encephalopathy syndrome","volume":"7","author":"Hussein","year":"2017","journal-title":"Neurol. Clin. Pract."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:39:05Z","timestamp":1762843145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":14,"alternative-id":["S2468294222000399"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100548","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Posterior reversible encephalopathy syndrome associated with use of Atezolizumab for the treatment of relapsed triple negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100548","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100548"}}